Business
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":"Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate$1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor Day in New York City today. The event will include presentations from the Ligand senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. Scott Plesha, CEO of Pelthos Therapeutics, a Ligand partner, will also discuss the recent launch of Zelsuvmi. “2025 was an exciting year for Ligand, highlighted by meaningful advancements across our royalty portfolio and important contributions from our partners. Our outlook for the business has never been stronger. We are executing our strategy with clarity and commitment, and we believe this positions us well to continue delivering value for our shareholders while supporting the development of innovative medicines,” said Todd Davis, CEO of Ligand. At today’s event, Ligand’s senior management team will highlight: The company’s strong financial performance in 2025, driven by an estimated 40% increase in royalty revenue growth and an estimated 30% increase in core adjusted earnings per share growth1Key royalty revenue drivers for the company in 2026 include Filspari (Travere Therapeutics), Ohtuvayre (Merck), Capvaxive (Merck), Qarziba (Recordati S.p.A.), and Zelsuvmi (Pelthos Therapeutics)The company’s investment activity in 2025, which included a commitment of $130 million across six investments, and robust pipeline heading into 2026Deployable capital of $1 billion will drive long-term royalty revenue growth through disciplined allocationThe company’s royalty-generating technology platforms—Captisol® and NITRICIL™— that Ligand believes offer broad applicability and significant revenue growth Financial Overview and Outlook Today, Ligand will reiterate its 2025 guidance outlined in November: Total core revenue o...